OncoMatch/Clinical Trials/NCT05961111
A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors
Is NCT05961111 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Recombinant oncolytic herpes simplex virus type 1 (R130) for sarcoma.
Treatment: Recombinant oncolytic herpes simplex virus type 1 (R130) — 20 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Breast Carcinoma
Non-Small Cell Lung Carcinoma
Glioblastoma
Melanoma
Head and Neck Squamous Cell Carcinoma
Renal Cell Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard treatment
Failure of standard treatment or patient unwillingness to receive other antitumor therapy.
Cannot have received: endocrine therapy
Have had antitumor therapy, including endocrine, chemotherapy, radiotherapy, targeted therapy, immunotherapy and antitumor herbal therapy, 4 weeks prior to the first dose.
Cannot have received: chemotherapy
Have had antitumor therapy, including endocrine, chemotherapy, radiotherapy, targeted therapy, immunotherapy and antitumor herbal therapy, 4 weeks prior to the first dose.
Cannot have received: radiotherapy
Have had antitumor therapy, including endocrine, chemotherapy, radiotherapy, targeted therapy, immunotherapy and antitumor herbal therapy, 4 weeks prior to the first dose.
Cannot have received: targeted therapy
Have had antitumor therapy, including endocrine, chemotherapy, radiotherapy, targeted therapy, immunotherapy and antitumor herbal therapy, 4 weeks prior to the first dose.
Cannot have received: immunotherapy
Have had antitumor therapy, including endocrine, chemotherapy, radiotherapy, targeted therapy, immunotherapy and antitumor herbal therapy, 4 weeks prior to the first dose.
Cannot have received: antitumor herbal therapy
Have had antitumor therapy, including endocrine, chemotherapy, radiotherapy, targeted therapy, immunotherapy and antitumor herbal therapy, 4 weeks prior to the first dose.
Lab requirements
Blood counts
ANC ≥ 1.5 × 10^9/L, platelets ≥ 80 × 10^9/L, hemoglobin ≥ 85 g/L
Kidney function
serum creatinine (Cr) and blood urea nitrogen (BUN) within 1.5x ULN
Liver function
serum total bilirubin (TBIL) ≤ 2x ULN; ALT and AST ≤ 2.5x ULN (≤ 5x ULN with liver metastases)
laboratory tests during the screening period must meet the following requirements: a) absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L, platelets (PLT) ≥ 80 × 10^9/L, and hemoglobin (Hb) ≥ 85 g/L; b) serum creatinine (Cr) and blood urea nitrogen (BUN) within 1.5 times the upper limit of normal values; c) serum total bilirubin (TBIL) ≤ 2 times the upper limit of normal values; d) glutamic aminotransferase (ALT) and glutamic oxalacetic aminotransferase (AST) ≤ 2.5 times the upper limit of normal values; subjects with liver metastases do not exceed 5 times the upper limit of normal values; e) activated partial thromboplastin time (APTT), prothrombin time (PT) within 1.5 times the upper limit of normal values.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify